isatuximab: a ‘next-generation monoclonal antibody’
Published 6 years ago • 1.1K plays • Length 2:41Download video MP4
Download video MP3
Similar videos
-
1:26
emerging monoclonal antibodies for the treatment of multiple myeloma
-
2:10
ikema trial update: isatuximab in mm
-
6:50
an overview of the immunotherapy landscape in aml: antibodies, bispecifics, & car-t
-
0:53
the future of next-generation sequencing assays in myeloma treatment
-
3:28
a phase ib trial of fixed-volume isatuximab infusion in newly-diagnosed multiple myeloma
-
3:01
the impact of tet2 mutations on hematopoietic stem cell resilience to immune-related stress
-
28:00
the bioinformatics of neoantigen discovery and vaccine design
-
4:36
what is isatuximab? and how does it compare with daratumumab?
-
1:42
applying next-generation sequencing in the diagnosis of rare inherited anemias
-
3:41
emerging therapies for r/r myeloma
-
2:16
the utility of next-generation sequencing for multiple myeloma
-
1:53
the future of multiple myeloma treatment
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
3:54
the role of isatuximab in the management of mm
-
1:59
a subgroup analysis of majestec-1: teclistamab in multiple myeloma with high-risk features
-
3:30
isatuximab: an important new option in r/r mm
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
0:54
a research update in richter's transformation from ash 2023
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:00
the incorporation of immunotherapy into frontline all treatment
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial